Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy results in a high margin-negative resection rate in patients with borderline resectable pancreatic cancer, phase II trial data show.

Looking at chemotherapy administration at the outpatient’s facility during the study period, Rasschaert and team found that there was no significant difference in the mean number of FOLFOX/FOLFIRI (3.21 vs 3.15) and paclitaxel (3.88 vs 4.25) administrations in March–May 2020 versus March–May 2019.

Adjuvant treatment with a modified FOLFIRINOX regimen significantly improves survival relative to gemcitabine in patients with resected pancreatic ductal adenocarcinoma, according to findings presented at the ASCO Annual Meeting 2018, held in Chicago, Illinois, USA.

Presenting author Thierry Conroy provides an overview of the PRODIGE 24 trial showing adjuvant modified FOLFIRINOX outplays gemcitabine in patients with operable pancreatic cancer (3:58). Read the related news story Watch the accompanying expert commentary

Treatment with a modified XELIRI regimen offers an alternative to standard second-line therapy with FOLFIRI in patients with metastatic colorectal cancer, research conducted in Asia shows.

A greater proportion of the Western Washington patients than the British Columbian patients received first-line systemic therapy (79 vs 68%); FOLFOX was the most common regimen in Western Washington (39%), whereas FOLFIRI plus bevacizumab was most frequently used among the British Columbian patients (32%).

Women have an increased risk for adverse events associated with fluorouracil-based chemotherapy for colorectal cancer, suggests an analysis of the PETACC-3 trial.

Among 494 patients who received 12 cycles of FOLFIRI plus bevacizumab 5 mg/kg every 2 weeks of induction chemotherapy, median tumor control duration (TCD) was 15 months for the 247 who went on to receive bevacizumab maintenance therapy during chemotherapy-free intervals and the 247 who were observed.

Patients with resectable or borderline resectable pancreatic cancer who receive neoadjuvant chemoradiotherapy have better outcomes than their counterparts who proceed directly to surgery, suggest phase III trial results.

.” --- Lead investigator Alan Venook (University of California, San Francisco, USA) and team found comparable overall survival (OS), progression-free survival, and response rates among patients with untreated locally advanced or metastatic CRC wild-type for KRAS regardless of whether they received cetuximab or bevacizumab alongside combination chemotherapy with mFOLFOX6 or FOLFIRI.

Researchers report promising results from a phase I trial evaluating CPI-613, which targets mitochondrial metabolism, in combination with modified FOLFIRINOX chemotherapy for the treatment of metastatic pancreatic cancer.